KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) FCF Margin (2016 - 2025)

Historic FCF Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 42.84%.

  • Teva Pharmaceutical Industries' FCF Margin rose 87400.0% to 42.84% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.46%, marking a year-over-year increase of 19100.0%. This contributed to the annual value of 12.46% for FY2025, which is 19100.0% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported FCF Margin of 42.84% as of Q4 2025, which was up 87400.0% from 5.2% recorded in Q3 2025.
  • Teva Pharmaceutical Industries' FCF Margin's 5-year high stood at 47.5% during Q4 2023, with a 5-year trough of 13.94% in Q1 2021.
  • Over the past 5 years, Teva Pharmaceutical Industries' median FCF Margin value was 4.17% (recorded in 2025), while the average stood at 8.01%.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' FCF Margin tumbled by -180000bps in 2021, and later soared by 261000bps in 2023.
  • Teva Pharmaceutical Industries' FCF Margin (Quarter) stood at 7.39% in 2021, then surged by 190bps to 21.4% in 2022, then skyrocketed by 122bps to 47.5% in 2023, then dropped by -28bps to 34.1% in 2024, then rose by 26bps to 42.84% in 2025.
  • Its last three reported values are 42.84% in Q4 2025, 5.2% for Q3 2025, and 3.14% during Q2 2025.